Repository logo
 
Publication

Vedolizumab-associated psoriasis: until where does gut selectivity go?

dc.contributor.authorGuedes, Tiago Pereira
dc.contributor.authorPedroto, Isabel
dc.contributor.authorLago, Paula
dc.date.accessioned2022-07-12T10:32:30Z
dc.date.available2022-07-12T10:32:30Z
dc.date.issued2020
dc.description.abstractInflammatory Bowel Disease and Psoriasis are chronic inflammatory diseases that share common genotype, clinical course, and immunological features, although its relationship is still unclear. We report a 34-year-old woman with ileal Crohn's disease diagnosed 14 years ago, with the development of extensive, exudative scalp lesions after adalimumab therapy. Biopsies from skin lesions were compatible with vulgar psoriasis. The patient reports no personal or family history of psoriasis. Due to persistence and further worsening of skin lesions, paradoxical etiology to adalimumab was presumed and the drug was stopped with complete resolution of skin lesions and intestinal disease in remission under methotrexate. Due to pregnancy-planification methotrexate was stopped and, 8 months-after, systemic steroid-therapy was introduced due to moderate-to-severe intestinal flare. Vedolizumab was started and at the second infusion patient reported hair loss with no other complaints. Twelve months after vedolizumab initiation the patient reported reappearance of the extensive scalp and peri-fistula psoriatic lesions. Topical therapy was started but unsuccessfully and given the progressive worsening of the lesions, vedolizumab was suspended, with skin improvement seen 1 month after discontinuation. There are few case-reports of vedolizumab acting as a trigger to some dermatological conditions in IBD-patients, including psoriasis. The molecular mechanism behind it isn't fully understood. We present and discuss, to our knowledge, the first case in the literature of psoriasis triggered by vedolizumab in Crohn's disease.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationPereira Guedes T, Pedroto I, Lago P. Vedolizumab-associated psoriasis: until where does gut selectivity go?. Rev Esp Enferm Dig. 2020;112(7):580-581. doi:10.17235/reed.2020.6817/2019pt_PT
dc.identifier.doi10.17235/reed.2020.6817/2019pt_PT
dc.identifier.issn1130-0108
dc.identifier.urihttp://hdl.handle.net/10400.16/2707
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherAran Edicionespt_PT
dc.relation.publisherversionhttps://www.reed.es/ArticuloFicha.aspx?id=4702&hst=0&idR=86&tp=1&AspxAutoDetectCookieSupport=1pt_PT
dc.subjectInflammatory bowel diseasespt_PT
dc.subjectCrohn’s diseasept_PT
dc.subjectPsoriasispt_PT
dc.subjectVedolizumabpt_PT
dc.titleVedolizumab-associated psoriasis: until where does gut selectivity go?pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceSpainpt_PT
oaire.citation.endPage581pt_PT
oaire.citation.issue7pt_PT
oaire.citation.startPage580pt_PT
oaire.citation.titleRevista Española de Enfermedades Digestivaspt_PT
oaire.citation.volume112pt_PT
person.familyNamePereira Guedes
person.familyNamePedroto
person.familyNameLAGO VIEIRA DOS SANTOS
person.givenNameTiago
person.givenNameIsabel
person.givenNamePAULA MARIA
person.identifier.ciencia-id5B19-5E13-B1FA
person.identifier.ciencia-id5514-3FC4-9C62
person.identifier.orcid0000-0002-6582-6749
person.identifier.orcid0000-0001-6573-699X
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationa0ba789d-9a16-4e88-8d89-29b70c1e285f
relation.isAuthorOfPublicatione523f164-bf0d-4248-8069-53df9d926349
relation.isAuthorOfPublicationabe823e2-57bc-45ab-9ab5-a59cfe48dab5
relation.isAuthorOfPublication.latestForDiscoverye523f164-bf0d-4248-8069-53df9d926349

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Guedes - 2020 - Vedolizumab-associated psoriasis.pdf
Size:
537.71 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.35 KB
Format:
Item-specific license agreed upon to submission
Description: